The Risk of Ovarian Malignancy Algorithm (ROMA) algorithm was approved by the FDA in 2011 Research demonstrates that examining levels of HE4 and CA125 using the ROMA algorithm shows the highest accuracy in determining ovarian cancer risk in pre- and post-menopausal women who have an ovarian mass present